search
Back to results

ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients

Primary Purpose

in Vitro Fertilization

Status
Recruiting
Phase
Not Applicable
Locations
Vietnam
Study Type
Interventional
Intervention
Pentoxifylline
Sponsored by
Mỹ Đức Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for in Vitro Fertilization focused on measuring Pentoxifylline, Sperm selecting, Absolute asthenozoospermia, in Vitro Fertilization

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria: Sperm are completely immotile since PESA, TESE and MicroTESE Sperm are completely immotile after ejaculation Exclusion Criteria: Oocyte maturation cycle in vitro

Sites / Locations

  • IVFMD, My Duc HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

non-randomized trials

Arm Description

Outcomes

Primary Outcome Measures

Fertilization rate
Total number of zygotes fertilized / total number of MII oocytes. zygote sperm is defined as a 2PN zygote at the time of testing fertilization17±1hours after ICSI

Secondary Outcome Measures

Rate of good embryos on day 3
Total number of day 3 and type 2 embryos / total number of day 3 embryos at the time of embryo examination. Standard for grading embryo quality according to consensus Alpha and ESHRE (2011)
Rate of good embryos on day 5
Total number of day 5 embryos type 1 and type 2 / total number of day 3 embryos at the time of day 5 embryo examination. Standard for grading embryo quality according to consensus Alpha and ESHRE (2011)
Clinical pregnancy rate
Calculated by the number of clinical pregnancies / total number of patients participating in the study.
Progressing pregnancy rate
Calculated by the number of active pregnancies/total number of patients participating in the study.
Miscarriage rate
Calculated by the number of cases of ongoing miscarriage / total number of patients participating in the study.

Full Information

First Posted
July 3, 2023
Last Updated
July 10, 2023
Sponsor
Mỹ Đức Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05943353
Brief Title
ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients
Official Title
The Efficacy of Pentoxifylline on Sperm Selecting in Intracytoplasmic Sperm Injection (ICSI) of Absolute Asthenozoospermia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 2023 (Anticipated)
Primary Completion Date
August 2024 (Anticipated)
Study Completion Date
August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mỹ Đức Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Absolute asthenozoospermia is a rare condition in men with an occurrence frequency of 1/5000 and greatly affects fertility product. Previous studies have shown that the ovum can be fertilized with live but immotile sperm. However, the selection of live sperm for ICSI in immotile sperm samples is challenging for embryologists. Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. In Vietnam, the application of PTX in ICSI has not yet been done in assisted reproductive centers. It is necessary to evaluate the effectiveness of PTX on ICSI treatment results in order to replace traditional methods and optimize treatment outcomes for patients.
Detailed Description
Sperm motility is an important factor in sperm selection for intracytoplasmic sperm injection. Intracytoplasmic Sperm Injection (ICSI), affects the success of ICSI cycles. In cases of severe male factor infertility, if motile sperm are still observed, ICSI still has the potential to help improve fertilization rates and treatment outcomes for patients. In contrast, the absence of motile sperm after ejaculation greatly affects the fertilization rate and the success of the ICSI cycle. Absolute asthenozoospermia is a rare condition in men with an occurrence frequency of 1/5000 and greatly affects fertility product. In addition, complete immobility of sperm was also observed in cases of sperm collection from epididymal surgery (Percutaneous Epididymal Sperm Aspiration (PESA) or obtained from the testicles (Testicular Sperm Extraction (TESE). The characteristics of sperm samples obtained from the procedure are usually a high percentage of poor motility or complete immobility and cryopreservation of sperm may affect sperm motility and viability, especially for sperm samples from surgical collection. Previous studies have shown that the ovum can be fertilized with live but immotile sperm. However, the selection of live sperm for ICSI in immotile sperm samples is challenging for embryologists. Currently, the methods performed in this case include the hypo-osmotic swelling test (HOS test), the sperm tail flexibility test (STFT) and laser-assisted immotile sperm selection (LAISS). However, traditional methods such as HOS test and STFT have the common disadvantage of long operation time and the result of sperm selection can be false positive, LAISS method is reported to be highly effective but still has some negative effects disadvantages in terms of operation time, high operating costs and requiring professional qualifications. Besides the above methods, the use of chemical inducers for sperm selection has received more and more attention in recent years. Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. The study of Kovacic et al (2006) compared the embryology results of two groups of ICSI from spermatozoa with and without PTX use, in addition, the average ICSI time of 1 cycle (from time to time) initiation of sperm selection and immobilization until completion of the ICSI procedure) were evaluated in two groups. PTX shortened ICSI time (mean 30 minutes) compared with the control group (mean 120 minutes). In addition, when compared with the group that did not use PTX, the group that used PTX had higher fertilization results (66% vs 50.9%, P < 0.005) and a higher clinical pregnancy rate (38.3%) compared to 26.7%). In addition, the use of PTX is assessed to have no negative impact on sperm and the health of live children. Stephanie et al (2021) evaluated the effects of PTX use on the development and behavior of 3-year-old children born from the ICSI cycle. No abnormal growth was observed among 8 children born from ICSI-PTX cycle compared with 6/170 children in the control group (0% vs 3.5%, P=0.28). In addition, there was no difference in the percentage of children with behavioral abnormalities in the ICSI-PTX group compared with the control group (0% vs. 9.4%, P=1.00). The study showed that PTX has potential applications in ICSI to improve sperm motility in cases of complete immobility, helping to improve treatment outcomes for patients. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. In Vietnam, the application of PTX in ICSI has not yet been done in assisted reproductive centers. It is necessary to evaluate the effectiveness of PTX on ICSI treatment results in order to replace traditional methods and optimize treatment outcomes for patients. Therefore, the investigators performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
in Vitro Fertilization
Keywords
Pentoxifylline, Sperm selecting, Absolute asthenozoospermia, in Vitro Fertilization

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
non-randomized trials
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
Pentoxifylline
Intervention Description
Prominently, Pentoxyfilline (PTX) is a methylxanthine derivative, is an inhibitor of phosphodiesterase activity and increases intracellular cAMP levels, which play an important role in sperm motility. The ability of PTX to improve sperm motility was first recognized in the study of Turner et al (1978). One of the advantages of PTX is that it significantly reduces the time to find and select motile sperm in cases of completely immotile sperm. In recent years, many studies have demonstrated the effectiveness of PTX for the group of spermatozoa, sperm carrying severe abnormalities. Therefore, the use of a sperm motility inducer such as PTX is a potential method to replace traditional ICSI sperm selection methods. Therefore, we performed this study with the aim to evaluate the effectiveness of PTX to select sperm in ICSI on the group of sperm that were completely immotile after ejaculation and obtained from the procedure.
Primary Outcome Measure Information:
Title
Fertilization rate
Description
Total number of zygotes fertilized / total number of MII oocytes. zygote sperm is defined as a 2PN zygote at the time of testing fertilization17±1hours after ICSI
Time Frame
16-18 hours after ICSI-PTX
Secondary Outcome Measure Information:
Title
Rate of good embryos on day 3
Description
Total number of day 3 and type 2 embryos / total number of day 3 embryos at the time of embryo examination. Standard for grading embryo quality according to consensus Alpha and ESHRE (2011)
Time Frame
67-69 hours
Title
Rate of good embryos on day 5
Description
Total number of day 5 embryos type 1 and type 2 / total number of day 3 embryos at the time of day 5 embryo examination. Standard for grading embryo quality according to consensus Alpha and ESHRE (2011)
Time Frame
114-118 hours
Title
Clinical pregnancy rate
Description
Calculated by the number of clinical pregnancies / total number of patients participating in the study.
Time Frame
Clinical pregnancy is defined as the presence of an intrauterine gestational sac on ultrasound from 5 weeks of age
Title
Progressing pregnancy rate
Description
Calculated by the number of active pregnancies/total number of patients participating in the study.
Time Frame
An advanced pregnancy was defined as having at least one gestational sac with a fetal heartbeat up to 12 weeks of age
Title
Miscarriage rate
Description
Calculated by the number of cases of ongoing miscarriage / total number of patients participating in the study.
Time Frame
Progressive miscarriage is defined as: before the end of the 22nd week of pregnancy in which the fetus is no longer viable and expelled from the uterus.

10. Eligibility

Sex
Male
Gender Based
Yes
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Sperm are completely immotile since PESA, TESE and MicroTESE Sperm are completely immotile after ejaculation Exclusion Criteria: Oocyte maturation cycle in vitro
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tuong M Ho, M.D
Phone
+84903633377‬
Email
tuongho.ivfmd@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tuan M Vo, Bsc
Phone
+84969916537
Email
tuan.vm@myduchospital.vn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tuong M Ho, M.D
Organizational Affiliation
Mỹ Đức Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
IVFMD, My Duc Hospital
City
Ho Chi Minh City
Country
Vietnam
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tuong M Ho, M.D
Phone
+84903633377‬
Email
tuongho.ivfmd@gmail.com
First Name & Middle Initial & Last Name & Degree
Tuan M Vo, Bsc
Phone
+849699616537
Email
tuan.vm@myduchospital.vn

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

ICSI Using Pentoxifylline to Identify Viable Spermatozoa in Absolute Asthenozoospermia Patients

We'll reach out to this number within 24 hrs